ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Pulse Check: 3 Things You May Not Know About the Most Common Heart Rhythm Disorder

By: NewsUSA

(NewsUSA) - Pulse Check: 3 Things You May Not Know About the Most Common Heart Rhythm Disorder

Atrial fibrillation (AFib), otherwise known as an irregular or fluttering heartbeat, is the most common heart rhythm disorder. In fact, nearly one in every ten people older than 65 have AFib.1 September is National AFib Awareness Month, which is a great time to take a pulse check on your heart health. Here are three misconceptions about AFib and the facts you need to know.

Misconception #1: AFib Symptoms are Easy to Spot

This is not always true – some people don’t know they have AFib until they are diagnosed at a doctor’s appointment or it causes a larger medical concern. It’s often at routine checkups when AFib is diagnosed.  

For others, AFib feels like butterflies or a flopping fish in the chest, according to StopAFib.org.

AFib is a progressive disease meaning that when left untreated or undiagnosed, patients are five times more likely to have a stroke.2 Knowing the signs and symptoms of AFib can help you and your doctor catch it earlier:    

  • Heart sensations, sometimes called palpitations, which may include irregular, thumping, or pounding heartbeats    
  • Feeling like your heart is racing    
  • Chest discomfort or pain    
  • Fainting or lightheadedness    
  • Fatigue, shortness of breath, or weakness

Misconception #2: Medication is My Only Treatment Option

Currently, medications to prevent and treat irregular heart rhythms, known as antiarrhythmic drugs, don’t work for half of people who take them.3,4,5 Some patients with AFib may be candidates for a minimally invasive procedure called cryoablation. During the procedure, the Medtronic Artic Front™ Cryoballoon targets electrical signals to get your heart rhythm back on track and can be used as the first line therapy approach for a patient experiencing AFib.

Misconception #3: Everyone’s AFib is the same

According to StopAFib.org, different people experience different AFib symptoms. The best thing you can do is go talk to your doctor if you think you’re having symptoms. To better understand your specific condition, your doctor may recommend an insertable heart monitor that watches your heart continuously around the clock to detect abnormal heart rhythms including AFib.6  Long-term monitoring with the Medtronic LINQ™ family of insertable cardiac monitors (ICMs) can help your doctor get a better picture of how your heart is doing over time and detect episodes of AFib. Because AFib is a progressive condition—meaning it worsens over time—early treatment is crucial. When a heart monitor detects AFib, your doctor can help you get on the treatment course that is right for you. Your long-term heart monitor will continue to give your doctor the information needed to know if your treatment is working or if you need to make changes over time.

Always talk to your doctor about risks, diagnosis, and treatment information.

Possible risks associated with the implant of the LINQ™ Family ICM’s include, but are not limited to, infection at the surgical site, device migration, erosion of the device through the skin and/or sensitivity to the device material.  Risks associated with the Artic Front™ Cryoballoon may include bleeding and bruising where the catheter was inserted, cough, shortness of breath, infection, temporary or permanent stroke, severe complications leading to hospitalization or potentially death. Always talk with your doctor about risks, diagnosis, and treatment information for AFib.

To learn more about atrial fibrillation, available treatment options and to identify a specialist near you, visit: www.Medtronic.com/AFmonth    

  1. Centers for Disease Control and Prevention (CDC), Worldwide Epidemiology of Atrial Fibrillation, A Global Burden of Disease 2010 Study    
  2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998 Oct 16;82(8A):2N-9N. doi: 10.1016/s0002-9149(98)00583-9. PMID: 9809895.    
  3. Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Engl J Med. January 28, 2021;384(4):316-324.    
  4. Kuniss M, Pavlovic N, Velagic V, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace. March 17, 2021:euab029.    
  5. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. January 28, 2021;384(4):305-315.    
  6. Majos E, Dabrowski R. Significance and Management Strategies for Patients with Asymptomatic Atrial Fibrillation. J Atrial Fibrillation. February 28, 2015;7(5):1169.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.